Market Cap | 69.35M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -8.22M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 15.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -4.00% |
Dividend | N/A | Price/Book | 5.20 | EPS next 5Y | - | 52W High Chg | -72.00% |
Recommedations | - | Quick Ratio | 0.99 | Shares Outstanding | 2.16M | 52W Low Chg | 113.00% |
Insider Own | 7.32% | ROA | -57.77% | Shares Float | 1.93M | Beta | 3.17 |
Inst Own | 9.58% | ROE | -29.12% | Shares Shorted/Prior | 393K/93.38K | Price | 1.70 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 679,187 | Target Price | - |
Oper. Margin | - | Earnings Date | Mar 29 | Volume | 1,298,762 | Change | 1.80% |
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.